Nexalin Technology, Inc.
$0.51
-0.0235 (-4.41%)
Transforming Mental Health with Advanced Neurostimulation
Join the Nexalin Technology, Inc. Investor Community
Get the latest news and company updates delivered straight to your inbox. Subscribe for free to stay ahead of the story and follow Nexalin Technology, Inc. as new developments unfold.
Company Overview
Nexalin Technology is a pioneering medical device company advancing non-invasive neurostimulation to address the global mental health crisis. Powered by its proprietary Deep Intracranial Frequency Stimulation (DIFS™), Nexalin’s Gen-2 device and Gen-3 HALO™ Clarity headset target deep brain structures linked to mental health and systemic conditions—without drugs or side effects. A growing body of peer-reviewed research, supported by advanced neuroimaging modalities such as fMRI, EEG, and MEG, has demonstrated DIFS™’ ability to normalize dysfunctional brain activity and produce clinically meaningful improvements across multiple indications, including Alzheimer’s disease, ADHD, depression, and insomnia.
Nexalin recently launched its AI-driven NeuroCare® virtual clinic in collaboration with UC San Diego, enabling at-home treatment, real-time monitoring, and a scalable, subscription-based care model that enhances accessibility and long-term patient engagement. The company is also advancing a pivotal, randomized clinical trial of its HALO™ Clarity headset for insomnia to support a planned FDA de novo submission, targeting a large and underserved market. With regulatory approvals in China, Brazil, and Oman, and CE Mark targeting underway, Nexalin continues to expand globally. The company also serves as Industry Co-Chair of the National TBI Registry Coalition and is supporting UC San Diego’s clinical trials on PTSD and TBI in veterans, underscoring its leadership in neurohealth innovation.
Value Proposition
Nexalin Technology is redefining the treatment of mental health and neurological disorders through its proprietary, non-invasive Deep Intracranial Frequency Stimulation (DIFS™) platform—positioning the Company at the convergence of medical devices, neuroscience, and digital health. Unlike conventional neuromodulation approaches that primarily target surface-level brain activity, Nexalin’s technology is designed to penetrate and regulate deep brain structures and large-scale neural networks implicated in conditions such as depression, Alzheimer’s disease, insomnia, PTSD, and ADHD. This differentiated mechanism of action is increasingly validated by a growing body of peer-reviewed research utilizing advanced neuroimaging tools—including fMRI, EEG, and MEG—which consistently demonstrate objective normalization of abnormal brain activity alongside meaningful clinical improvement.
The Company’s next phase of growth is being driven by the integration of its Gen-3 HALO™ Clarity headset with NeuroCare®, Nexalin’s newly launched AI-driven virtual clinic platform developed in collaboration with UC San Diego. This integrated ecosystem represents a fundamental shift in how brain-health therapies are delivered—enabling at-home treatment, real-time physician monitoring, and continuous data capture within a subscription-based model. By combining a medical device with a scalable digital health infrastructure, Nexalin is evolving beyond a traditional device company into a recurring revenue, data-driven care platform with the potential for high-margin, long-term patient engagement.
At the same time, Nexalin is advancing a broad and expanding clinical pipeline targeting large, underserved markets. Most notably, the Company is initiating a pivotal, randomized, triple-blinded clinical trial evaluating HALO™ Clarity for insomnia, designed to support a planned FDA de novo submission. With approximately 30 million adults in the United States affected by insomnia—and widespread dissatisfaction with existing pharmacological treatments—this represents a significant commercial opportunity and a key regulatory inflection point. Importantly, prior clinical data have already demonstrated statistically significant improvements in sleep outcomes without meaningful adverse effects, reinforcing the potential for a safe, drug-free alternative. Beyond insomnia, Nexalin continues to generate clinical evidence across Alzheimer’s disease, ADHD, depression, PTSD, TBI, and substance use disorders, underscoring the versatility and scalability of the DIFS™ platform.
Nexalin’s strategy is further supported by an expanding global regulatory footprint, existing approvals in multiple international markets, and ongoing engagement with the FDA across several indications. The Company’s robust intellectual property portfolio, extending through 2040, reinforces its competitive moat, while its leadership role in initiatives such as the National TBI Registry Coalition and collaborations with leading institutions enhance its credibility and visibility within both clinical and government channels.
Taken together, Nexalin represents a differentiated investment opportunity built on three reinforcing pillars: a clinically validated, next-generation neurostimulation platform with objective imaging-based evidence; a scalable, AI-enabled virtual care model capable of generating recurring revenue and long-term patient data; and a rapidly advancing clinical and regulatory pipeline targeting some of the largest and most underserved markets in healthcare. With multiple near-term catalysts—including clinical trial progression, regulatory milestones, and continued platform deployment—Nexalin is positioned to drive meaningful value creation as it works to establish a new standard of care in brain health.
Investor Presentation
Investment Highlights
Proprietary Technology with Expanding Clinical Validation
- Growing body of peer-reviewed research supported by advanced neuroimaging (fMRI, EEG, MEG, PET) demonstrates DIFS™’ ability to normalize dysfunctional brain activity and regulate large-scale neural networks—differentiating Nexalin from surface-level stimulation approaches
- Peer-reviewed results published in Radiology demonstrated that Nexalin’s 40-Hz DIFS™ stimulation significantly improved cognitive performance and enhanced brain network connectivity in patients with mild Alzheimer’s disease; multiple studies showing cognitive and brain network improvements in Alzheimer’s and dementia
- Peer-reviewed study in Journal of Affective Disorders shows tech significantly reduces blood pressure in patients with depression—highlighting broader therapeutic potential
- Peer-reviewed clinical study in Molecular Psychiatry demonstrated DIFS™ improves attention and normalizes brain activity in patients with ADHD, with measurable changes in gamma-frequency brain activity and network communication
- Independent clinical trials at UC San Diego evaluating HALO™ Clarity headset for PTSD and traumatic brain injury (TBI), including deployment of 50+ devices
Next-Generation Virtual Care Platform Enabling Scalable, Recurring Revenue Model
- Launch of NeuroCare®, Nexalin’s AI-driven virtual clinic developed in collaboration with UC San Diego, enabling remote treatment, real-time monitoring, and enhanced patient access
- Integrated with Gen-3 HALO™ Clarity headset to deliver at-home, drug-free neurostimulation therapy under physician oversight
- Subscription-based model supports recurring revenue, long-term patient engagement, and continuous data capture for optimized outcomes
- AI-powered Electronic Data Capture (EDC) and Patient Monitoring System (PMS) provide real-time data for personalized care and physician oversight
Expanding Pipeline Targeting Large, Underserved Indications
- Addressing major mental health and neurological conditions including depression, insomnia, PTSD, TBI, Alzheimer’s, ADHD, and substance use disorders
- Newly initiated pivotal, randomized, triple-blinded clinical trial of HALO™ Clarity for insomnia designed to support planned FDA de novo submission—targeting a multi-billion-dollar market with ~30 million U.S. sufferers
- Prior clinical data in insomnia demonstrated statistically significant improvements in sleep metrics with no meaningful adverse effects, supporting regulatory pathway
- Newly allowed U.S. patent expands Nexalin’s technology into treatment of opioid and other substance use disorders (OUD, SUD, AUD, stimulant addiction)
Global Regulatory Progress and Commercialization Strategy
- Gen-2 15mA device approved in China, Brazil, Israel, and Oman; continued FDA engagement across multiple indications including Alzheimer’s, dementia, and insomnia
- Planned de novo FDA submission for insomnia supported by upcoming pivotal trial, representing a key regulatory inflection point
- CE Mark targeting planned to enable European commercialization
- Strategic partnerships and research collaborations with leading institutions, including UC San Diego and Lindus Health for clinical execution
Robust Intellectual Property and Differentiated Technology Platform
- Proprietary DIFS™ waveform designed to penetrate deep brain structures and modulate network-level activity, supported by objective imaging data across multiple indications
- IP secured through 2040 across multiple therapeutic categories and global markets
- Platform technology supports expansion across a wide range of neuropsychiatric and neurodegenerative disorders
Experienced Leadership and Strategic Positioning in Neurohealth
- Led by CEO Mark White, an innovator in digital medical markets, supported by a highly experienced team and collaborations with leading institutions
- Military & Government Advisory Board includes General Wesley Clark (Ret.), former NATO Supreme Allied Commander Europe
- Leadership role in National TBI Registry Coalition and active engagement in veteran-focused brain health initiatives
- Positioned at the intersection of medical devices, digital health, and AI-driven care delivery
Attractive Market Opportunity and Third-Party Validation
- Mental health market projected to reach $537 billion by 2030; neuromodulation market forecasted at $11 billion by 2028
- Expansion into insomnia and virtual care further increases total addressable market and revenue visibility
- Buy rating and $4 price target from Maxim
Sign Up For NXL Email News Alerts
Disclosure
RedChip Companies, Inc. research reports, company profiles, and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.
RedChip Visibility is a division of RedChip Companies, Inc. and offers research services to paying clients. In the purview of Section 17(b) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention to the fact that RedChip Companies Inc. is an investor relations firm hired by certain companies to increase investor awareness to the small-cap equity community.
Stock market investing is inherently risky. RedChip Companies is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles, or in other investor relations materials or presentations that it publishes electronically or in print.
We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at www.sec.gov and/or the Ontario Securities Commission (“OSC”) at www.osc.gov.on.ca.
Nexalin (NXL) is a client of RedChip Companies. NXL agreed to pay RedChip a one-time $45,000 fee for a national TV ad campaign that aired weekdays from April 1 through April 11, 2024, a one-time $40,000 fee for a national TV ad campaign aired weekdays from June 17 to June 28, 2024, a one-time $40,000 fee for a national TV ad campaign aired weekdays from October 16 to October 30, 2024, and a one-time $78,000 fee for a four-week national TV ad campaign aired weekdays from February 3 to February 28, 2025.
Investor awareness services and programs are designed to help small-cap companies communicate their investment characteristics. RedChip investor awareness services include the preparation of a research profile(s), multimedia marketing, and other awareness services.